Palatin Technologies

Palatin Technologies is a biopharmaceutical company dedicated to discovering and developing innovative therapeutics for patients living with inflammatory and autoimmune conditions. With a focus on modulating the melanocortin peptide receptor system, Palatin Technologies is pioneering first-in-class medicines that address critical physiological activities such as food intake, energy balance, desire, arousal, and the resolution of harmful inflammation. The company's commitment to innovation has led to the successful development of Vyleesi®, the first FDA-approved melanocortin-based therapeutic for women with hypoactive sexual desire disorder (HSDD).

Building on the success of Vyleesi® and their extensive experience in melanocortin-based therapeutics, Palatin Technologies is now focused on developing therapeutics that leverage the key role of the melanocortin system in resolving harmful inflammation. This strategic direction has the potential to treat a wide range of diseases affecting the eye, gastrointestinal system, and kidney. Their most advanced ocular product, PL9643, is a topical treatment for dry eye disease, poised to enter Phase 3 clinical trials. Palatin Technologies also has therapeutics in earlier stages of development for ophthalmic indications, including non-infectious uveitis, retinopathies, and corneal diseases.

Palatin Technologies is committed to establishing the broad utility of therapeutics that modulate the activity of the melanocortin system, with plans to conduct proof-of-concept clinical studies in ulcerative colitis and kidney disease. Headquartered in Cranbury, US, Palatin Technologies continues to drive innovation and create value for its shareholders by developing groundbreaking therapies that improve the lives of patients. We invite the manager of Palatin Technologies to create a customized and exclusive company showcase and product listing on our platform to further enhance your company's visibility and commercial opportunities.